Margins improve, but device growth still needs proof
- Merit sells proprietary medical devices used in cardiology, radiology, oncology, critical care, endoscopy, and related procedures.
- The bull case rests on the Continued Growth Initiatives plan, record Q1 2026 operating margin of 19.7%, and better use of acquisitions.
- The View Point Medical deal could lift oncology growth, with management pointing to about $15 million of 2027 revenue, 20% growth, and 70% gross margins.
- The bear case is that OEM demand stays uneven, APAC stays weak, and the roughly $15 million 2026 tariff headwind does not go away.
- Finn's middle-of-the-road score fits the story: the company is improving, but the next leg depends on execution, not hype.
Better margins, harder proof
Merit is in a cleaner spot than it was a few years ago. Full-year 2025 sales were $1.516 billion, up 11.8%, and gross margin rose to 48.7%. In Q1 2026, operating margin reached a record 19.7%. That supports the bull case that the Continued Growth Initiatives program is doing real work.
The next test is growth quality. Merit has bought useful assets, including View Point Medical in oncology, C2 CryoBalloon in endoscopy, Cook Medical lead management products, and Biolife assets. The View Point deal is the clearest new swing. Management says it triples the addressable breast biopsy market and could add about $15 million of revenue in 2027, growing 20% with 70% gross margins.
The bear case is not broken. OEM sales fell 14% year over year in Q1 2026 because of inventory destocking tied to product transfers to Tijuana. Management expects OEM to return to mid-single-digit growth in Q2, based on early orders. Investors need to see that happen, not just hear it promised.
Tariffs also keep the story from being simple. A Supreme Court ruling may help Merit recover some tariff costs, but the administration can challenge reimbursement through May 2026. That leaves the projected roughly $15 million 2026 tariff impact unresolved. The stock deserves credit for margin progress, but the proof points are still in front of it.
Many small tools for serious procedures
Merit makes and sells medical devices used by doctors during interventional, diagnostic, and therapeutic procedures. These are not consumer products. They are tools used in hospitals, clinics, and procedure rooms, often in areas like cardiology, radiology, oncology, critical care, and endoscopy.
The business has two broad revenue buckets. Foundational products are access and enabling tools, and they represented about two-thirds of 2025 revenue. Therapeutic products treat disease more directly, and they represented about one-third of 2025 revenue. Therapeutic products are where Merit is trying to add more growth through oncology, endoscopy, renal, and cardiac therapies.
This model can work well when Merit sells proprietary devices, improves factories, and folds acquired products into its sales force. It can break when hospital demand slows, OEM customers reduce inventory, shipping is delayed, tariffs lift costs, or recalls create operational noise.
Where the growth can come from
Foundational access and enabling products
These products help doctors get into the body and perform procedures safely. They made up about two-thirds of 2025 revenue, so they fund much of the company.
Oncology, SCOUT, and View Point Medical
The View Point Medical acquisition added the OneMark Detection Imaging System and tissue markers. Management says the deal triples Merit's addressable breast biopsy market.
Endoscopy, EsophyX Z+, C2 CryoBalloon, and Resilience TTS
Endoscopy sales grew 33.0% in 2025. The newer C2 CryoBalloon technology and U.S. launch of the Resilience TTS Esophageal Stent add more products for digestive disease care.
WRAPSODY
WRAPSODY is a commercial growth target for 2026, with management aiming for $7 million of revenue. Reimbursement timing hurt the early launch, so tracking sales matters.
Cardiac therapies and lead management
Merit added Cook Medical's lead management portfolio and Biolife assets. These deals helped expand cardiac therapy sales and give the company more products to sell into existing hospital channels.
OEM products
Merit also sells to other medical device companies. This can be useful volume, but Q1 2026 showed the risk when customers reduce inventory.
Two buckets now matter
Merit now reports revenue as Foundational and Therapeutic. The mix below uses management's Q1 2026 disclosure that Foundational was about two-thirds of 2025 revenue and Therapeutic was about one-third.
What could trip the plan
Tariff refund risk
Medium impact · Medium oddsMerit still has a projected roughly $15 million 2026 tariff headwind. The Supreme Court ruled that some IEEPA tariffs were not authorized, but the company said the administration can still challenge reimbursement through May 2026. If refunds are delayed or denied, margin gains could be harder to keep.
OEM destocking lasts longer
Medium impact · Medium oddsOEM sales fell 14% year over year in Q1 2026. Management blamed temporary U.S. inventory destocking tied to product line transfers to Tijuana and expects mid-single-digit growth in Q2. If that recovery misses, the growth story weakens.
View Point integration misses
Medium impact · Medium oddsThe View Point Medical deal is important because it expands oncology and could bring about $15 million of 2027 revenue at 70% gross margins. That upside depends on Merit integrating the product, training sales teams, and winning customers. A slow start would reduce the value of the deal.
Recall and quality control pressure
Medium impact · Low oddsA recent Renal platform supply chain issue led to a Class I recall. Management expects the 2026 financial impact to be immaterial, but Class I recalls are serious because they involve a risk of severe harm. More quality issues could hurt trust with hospitals and regulators.
APAC and shipping disruption
Low impact · Medium oddsInternational sales face macro pressure in APAC. The Middle East conflict also created fuel surcharges and shipping issues, and Merit said about $1.5 million of Q1 revenue was left on the table because shippers could not pick up product. These are not thesis-breaking today, but they can chip away at growth.